Introduction
Ertugliflozin is a new SGLT2 inhibitor drug jointly developed by Pfizer and Merck. In December 2017, the US FDA approved its listing, with the trade name Steglatro, which is clinically used for the treatment of adult patients with type 2 diabetes. It has not yet been marketed in China.
Function
Ertugliflozin series impurities are used for the research and inspection of related substances in the drug research of Egliflozin.
Ertugliflozin (CAS 1210344-57-2) is a pharmaceutical-grade SGLT2 inhibitor API. Its molecular formula is C22H28N2O6. The compound undergoes high-purity crystallization and rigorous purification to meet global pharmacopeial standards.
Contraindicated in severe renal impairment, dialysis, or type 1 diabetes. Requires strict storage at controlled room temperature (20-25°C) with protection from moisture and light to maintain stability.